The Pharmacological Efficacy of the Anti-Il17 Scfv and Stnfr1 Bispecific Fusion Protein in Inflammation Mouse Stimulated by LPS.

Yongbi Yang,Teng Zhang,Hongxue Cao,Dan Yu,Tong Zhang,Shaojuan Zhao,Xiaohui Jing,Liying Song,Yunye Liu,Ruixiang Che,Xin Liu,Deshan Li,Guiping Ren

DOI: https://doi.org/10.1016/j.biopha.2017.05.147

IF: 7.419

2017-01-01

Biomedicine & Pharmacotherapy

Abstract:Acute lung injury (ALI) is still a leading cause of morbidity and mortality in critically ill patients. Recently, our study found that a bispecific fusion protein treatment can ameliorate the lung injury induced by LPS. However, the molecular mechanisms which bispecific fusion protein ameliorates acute lung injury remain unclear. In this study, we found that the bispecific fusion protein treatment inhibited the nuclear transcription of NF-κB in confocal laser scanning fluorescence microscopy, the bispecific fusion protein exert protective effects in the cell model of ALI induced by lipopolysaccharide (LPS) via inhibiting the nuclear factor κB (NF-κB) signaling pathway and mediate inflammation. Moreover, the treatment of the bispecific fusion protein show its efficacy in animal models stimulated by LPS, the results of real-time PCR and ELISA demonstrate that bispecific fusion protein treatment effectively inhibited the over-expression of inflammatory cytokines(tumor necrosis factor α, interleukin 1β and interleukin 17). In addition, LPS-challenged mice exhibited significant lung injury characterized by the deterioration of histopathology, which was meliorated by bispecific fusion protein treatment. Collectively, these results demonstrate that bispecific fusion protein treatment ameliorates LPS-induced ALI through reducing inflammatory cytokines and lung inflammation, which may be associated with the decreased the nuclear transcription of NF-κB. The bispecific fusion protein may be useful as a novel therapy to treat ALI.